#18 Jurjen Versluis: Transplant for high-risk MDS
Release Date:
Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study.
https://pubmed.ncbi.nlm.nih.gov/37607457/
ALSO AS VIDEO ON
https://youtu.be/JbHS_-2sJQc
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
#18 Jurjen Versluis: Transplant for high-risk MDS